Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

19
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
19
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

18
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
18
Liver Regeneration01:24

Liver Regeneration

3.5K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.5K
Hepatic Portal System01:21

Hepatic Portal System

2.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
2.9K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

172
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scientific Opinion of Flavouring Group Evaluation 407 (FGE.407): 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid.

EFSA journal. European Food Safety Authority·2020
Same author

Safety assessment of the substance 'Tungsten Oxide' for use in food contact materials.

EFSA journal. European Food Safety Authority·2020
Same author

Scientific Opinion on Flavouring Group Evaluation 63, Revision 3 (FGE.63Rev3): aliphatic secondary alcohols, ketones and related esters evaluated by JECFA (59th and 69th meetings) structurally related to saturated and unsaturated aliphatic secondary alcohols, ketones and esters of secondary alcohols and saturated linear or branched-chain carboxylic acids evaluated by EFSA in FGE.07Rev4.

EFSA journal. European Food Safety Authority·2020
Same author

Safety evaluation of the food enzyme pullulanase from <i>Pullulanibacillus naganoensis</i> strain AE-PL.

EFSA journal. European Food Safety Authority·2020
Same author

Safety evaluation of the food enzyme peroxidase obtained from soybean (<i>Glycine max</i>) hulls.

EFSA journal. European Food Safety Authority·2020
Same author

Safety assessment of the mixture of methyl-branched and linear C<sub>14</sub>-C<sub>18</sub> alkanamides, derived from fatty acids, for use in food contact materials.

EFSA journal. European Food Safety Authority·2020
Same journal

Skin Cancer: Management of Cutaneous Melanoma.

FP essentials·2026
Same journal

Skin Cancer: Management of Actinic Keratoses and Keratinocyte Carcinomas.

FP essentials·2026
Same journal

Skin Cancer: Diagnosis.

FP essentials·2026
Same journal

Skin Cancer: Screening and Prevention.

FP essentials·2026
Same journal

Skin Cancer.

FP essentials·2026
Same journal

Obesity Management: Surgical Interventions.

FP essentials·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.4K

Liver Disease: Hepatitis C.

Joshua St Louis1, Katrina Baumgartner1, Julia Cooper2

  • 1Department of Family Medicine - Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111.

FP Essentials
|December 2, 2021
PubMed
Summary
This summary is machine-generated.

Routine screening for hepatitis C virus (HCV) is recommended for all adults. Effective primary care-based treatments offer over 95% cure rates for chronic hepatitis C infection.

More Related Videos

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.3K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.3K

Related Experiment Videos

Last Updated: Oct 11, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.4K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.3K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.3K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) affects millions in the US, with 2.5 million experiencing chronic infection.
  • Untreated chronic HCV can lead to severe liver conditions like cirrhosis and hepatocellular carcinoma.
  • Current guidelines advocate for universal, one-time HCV screening for adults and risk-based testing.

Purpose of the Study:

  • To outline current management strategies for chronic hepatitis C.
  • To emphasize the role of primary care physicians in HCV treatment.
  • To highlight the efficacy of modern pangenotypic regimens.

Main Methods:

  • Review of current screening guidelines for hepatitis C virus (HCV).
  • Description of primary care-based treatment protocols for eligible adults.
  • Utilizing pangenotypic regimens such as glecaprevir-pibrentasvir or sofosbuvir-velpatasvir.
  • Confirmation of treatment success via sustained virologic response (SVR) at 12 weeks post-treatment.

Main Results:

  • Hepatitis C management has been simplified, enabling primary care physicians to treat most patients.
  • Pangenotypic regimens achieve over 95% rates of virologic cure (SVR).
  • Comprehensive pretreatment evaluation is crucial for successful treatment planning.

Conclusions:

  • Early treatment of chronic hepatitis C prevents severe liver disease progression.
  • Primary care-based treatment models are effective and accessible for most patients.
  • Patients not achieving SVR require referral to specialists for further management.